Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × sintilimab × Endocrine × Clear all

Phase

Status

Unknown 2 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 50 Thoracic 9 Head & Neck 7 Gynecologic 4 CNS 3 Breast 3 Other solid neoplasm 2 Sarcoma 1 Other neoplasm 1 NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 14 Magnetic Resonance Spectroscopy 13 gallium Ga 68 dotatate 8 Specimen Handling 8 Everolimus 8 pembrolizumab 7 Cisplatin 7 cabozantinib 5 Etoposide 5 177Lu-octreotide, DOTA(0)-Tyr(3)- 5 lanreotide 4 Fluorodeoxyglucose F18 4 trametinib 3 surufatinib 3 olaparib 3 lenvatinib 3 fluorodopa F 18 3 dabrafenib 3 cemiplimab 3 X-Rays 3 Transurethral Resection of Prostate 3 Thyrotropin Alfa 3 Somatostatin 3 Nivolumab 3 Lutetium-177 3 Iodine-131 3 Injections 3 Drug Therapy 3 Cyclophosphamide 3 Carboplatin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05165407 2025-03-14

NESSIE

Peking University

Phase 2 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡